Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy.

BACKGROUND: Cancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. Nanoparticles have potential in cancer treatment because they offer advantages such as biocompatibility, greater stability, and precise targeting capabilities. METHOD: We synthesized an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 (TLR7) ligand, sugar chains, and peptide antigens for cancer immunotherapy. The potential of iGN was investigated using a therapeutic animal model. RESULTS: In murine models, iGN effectively induces antigen-specific cytotoxic T cells, demonstrating prophylactic and therapeutic efficacy against tumor growth. iGN stimulates antigen-presenting cells via the TLR7-MYD88 pathway, enhancing antigen presentation and priming of cytotoxic T cells. Combination therapy with iGN and anti-PD-1 antibodies improves survival of tumor-bearing mice. CONCLUSIONS: These findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.